Analyst Clémence Thiers of Stifel Nicolaus maintained a Buy rating on MaaT Pharma (MAAT – Research Report), retaining the price target of €22.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Clémence Thiers has given his Buy rating due to a combination of factors that highlight MaaT Pharma’s promising outlook. The company’s lead product, MaaT013, has received a positive final review from the Data Safety Monitoring Board (DSMB), which underscores its strong efficacy in treating acute Graft-versus-Host Disease (aGvHD). This endorsement not only confirms the drug’s potential but also enhances the credibility of MaaT Pharma’s broader therapeutic platform, which could reduce risks associated with future developments.
Furthermore, the pivotal ARES Phase 3 study demonstrated impressive results, with a gastrointestinal overall response rate significantly surpassing expectations and a notable survival rate at one year. These outcomes position MaaT013 as a potentially vital treatment option in a field with limited alternatives. The anticipated submission of the marketing authorization application to the European Medicines Agency in mid-2025, along with strategic plans for commercialization and partnerships, further supports the Buy rating, as these steps are likely to drive future growth and value for shareholders.
In another report released on March 12, Kepler Capital also maintained a Buy rating on the stock with a €16.50 price target.